

## Pharmaceutical Needs Assessment

### SUMMARY

- 1.1 The Health and Social Care Act 2012 transferred the responsibility for developing and updating Pharmaceutical Needs Assessments (PNAs) from Primary Care Trusts (PCTs) to Health and Wellbeing Boards (HWBs). The production of a PNA became the responsibility of Derby Health and Wellbeing Board from 1 April 2013.
- 1.2 In accordance with regulations, each Health and Well-being Board must:
  - Assess needs for pharmaceutical services in its area
  - Publish a statement of its first assessment and of any revised assessment.
- 1.3 The development of a PNA is a separate duty to that of developing JSNA as PNAs will inform commissioning decisions by local authorities (public health services from community pharmacies) and by NHS England and clinical commissioning groups (CCGs).
- 1.4 There is a minimum information requirement for PNAs. The minimum information requirements can be found in Appendix 2.
- 1.5 HWBs will be required to produce the first assessment by 1 April 2015.
- 1.6 HWBs must consult certain bodies at least once during the process of developing the PNA. There is a minimum period of 60 days for consultation responses.
- 1.7 A Derbyshire and Derby City Pharmaceutical Needs Assessment Steering Group has been established to oversee the PNA process and ensure that the PNA meets all the minimum requirements.
- 1.8 It is intended that a cross-County PNA is produced, overseen by the established Steering Group, which will include a discrete City component and will meet the minimum requirements of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.

### RECOMMENDATION

- 2.1 The Board is asked to note its responsibility to develop a PNA by 1 April 2015.
- 2.2 The Board agrees to the production of a joint/ aligned PNA covering both city and county overseen by the Derbyshire and Derby City Pharmaceutical Needs Assessment Steering Group.
- 2.3 The Board receives future updates and assurances as to the progress in developing a PNA covering the Derby Health and Wellbeing Board.

## REASONS FOR RECOMMENDATION

- 3.1 To support the Health and Wellbeing Board in delivering its statutory responsibility to develop and publish a PNA.

## SUPPORTING INFORMATION

- 4.1 The Health and Social Care Act 2012 amended the National Health Services Act 2006 and transferred the responsibility for developing and updating Pharmaceutical Needs Assessments (PNAs) from Primary Care Trusts (PCTs) to Health and Wellbeing Boards (HWBs). The production of a PNA became the responsibility of Derby Health and Wellbeing Board from 1 April 2013.
- 4.2 The pharmaceutical services to which each pharmaceutical needs assessment must relate are all the pharmaceutical services that may be provided under arrangements made by NHS England.
- 4.3 Responsibility for using PNAs as the basis for determining market entry to a pharmaceutical list transferred from PCTs to NHS England from 1 April 2013.
- 4.4 In accordance with regulations, each Health and Well-being Board must:
- Assess needs for pharmaceutical services in its area
  - Publish a statement of its first assessment and of any revised assessment.
- 4.5 The development of a PNA is a separate duty to that of developing JSNA as PNAs will inform commissioning decisions by local authorities (public health services from community pharmacies) and by NHS England and clinical commissioning groups (CCGs).
- 4.6 Schedule 1 Regulation 4(1) of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 sets out the minimum information that must be contained in a PNA which in summary is:
- Necessary services: current provision
  - Necessary services: gaps in provision
  - Other relevant services: current provision
  - Improvements and better access: gaps in provision
  - Other NHS services
  - How the assessment was carried out
  - Map of provision.

The minimum information requirements as set out in Schedule 1 can be found in Appendix 2.

- 4.7 HWBs will be required to produce the first assessment by 1 April 2015 and will be required to publish a revised assessment within three years of publication of their first assessment. HWBs will be required to publish a revised assessment as soon as is reasonably practical after identifying significant changes to the availability of pharmaceutical services since the publication of its PNA.

- 4.8 HWBs must consult the bodies set out in Regulation 8 at least once during the process of developing the PNA.
- There is a minimum period of 60 days for consultation responses; and
  - Those being consulted can be directed to a website address containing the draft PNA but can, if they request, be sent an electronic or hard copy version.
- 4.9 A Derbyshire and Derby City Pharmaceutical Needs Assessment Steering Group has been established to oversee the PNA process and ensure that the PNA meets, at least, all the minimum requirements.
- 4.10 The Steering Group includes the following membership: Derbyshire County Council Public Health; Derby City Council Public Health; all five Clinical Commissioning Groups relating to Derbyshire; Local Pharmaceutical Committee; NHS England Derbyshire and Nottinghamshire Area Team.
- 4.11 It is intended that a cross-County PNA is produced, overseen by the established Steering Group, which will include a discrete City version and will meet the minimum requirements of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.
- 4.12 **References:**
- Department of Health (2013) *Pharmaceutical needs assessments: Information Pack for local authority Health and Wellbeing Boards*. (Link: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/197634/Pharmaceutical\\_Needs\\_Assessment\\_Information\\_Pack.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/197634/Pharmaceutical_Needs_Assessment_Information_Pack.pdf))
- Department of Health (2013) *The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013* (Link: <http://www.legislation.gov.uk/uksi/2013/349/contents/made>)

## OTHER OPTIONS CONSIDERED

- 5.1 The establishment of a City-specific steering group was considered to oversee the production of a PNA on behalf of the Health and Wellbeing Board. This was, however, deemed to be an unnecessary duplication as the majority of the members have roles covering the entirety of the county and would therefore require their attendance at two meetings. Further, whilst Derby City Council (Public Health) will be commissioning pharmaceutical services based on a city boundary, the other primary commissioners (Derbyshire and Nottinghamshire Area Team and Southern Derbyshire CCG) cover a wider geography and a joint/ aligned PNA is beneficial.

**This report has been approved by the following officers:**

<b>Legal officer</b> <b>Financial officer</b> <b>Human Resources officer</b> <b>Estates/Property officer</b> <b>Service Director(s)</b> <b>Other(s)</b>	Derek Ward, Director of Public Health
<b>For more information contact:</b> <b>Background papers:</b> <b>List of appendices:</b>	Alison Wynn, 01332 643106, Alison.Wynn@derby.gov.uk None Appendix 1 – Implications Appendix 2 – Schedule 1: Information to be contained in PNAs

<b>IMPLICATIONS</b>
---------------------

**Financial and Value for Money**

- 1.1 None.

**Legal**

- 2.1 The Health and Social Care Act 2012 transferred responsibility for developing and updating of PNAs to Health and Wellbeing Boards (statutory sub-committee of the local authority). The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs.

**Personnel**

- 3.1 None.

**IT**

- 4.1 None.

**Equalities Impact**

- 5.1 One of the key purposes of the PNA is to set out the local need for pharmaceutical services. This will include consideration of inequalities in health outcomes and access to pharmaceutical services. PNA to be discussed with the Diversity Forums.

**Health and Safety**

- 6.1 None.

**Environmental Sustainability**

- 7.1 None.

**Property and Asset Management**

- 8.1 None.

**Risk Management**

- 9.1 The timeframe for publication in April 2015 is tight especially given the consultation period and there is a risk that it will not be ready for publication. A project plan will be in place, however, to ensure delivery but should there be any concerns about delivering to time the HWB will be alerted.

**Corporate objectives and priorities for change**

- 10.1 The production of a PNA will support the delivery of corporate objectives, particularly those relating to health and wellbeing and support identification of priorities for change.

**The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013: schedule 1 Regulation 4(1) - Information to be contained in pharmaceutical needs assessments**

**Necessary services: current provision**

1. A statement of the pharmaceutical services that the HWB has identified as services that are provided—
  - (a) in the area of the HWB and which are necessary to meet the need for pharmaceutical services in its area; and
  - (b) outside the area of the HWB but which nevertheless contribute towards meeting the need for pharmaceutical services in its area (if the HWB has identified such services).

**Necessary services: gaps in provision**

2. A statement of the pharmaceutical services that the HWB has identified (if it has) as services that are not provided in the area of the HWB but which the HWB is satisfied—
  - (a) need to be provided (whether or not they are located in the area of the HWB) in order to meet a current need for pharmaceutical services, or pharmaceutical services of a specified type, in its area;
  - (b) will, in specified future circumstances, need to be provided (whether or not they are located in the area of the HWB) in order to meet a future need for pharmaceutical services, or pharmaceutical services of a specified type, in its area.

**Other relevant services: current provision**

3. A statement of the pharmaceutical services that the HWB has identified (if it has) as services that are provided—
  - (a) in the area of the HWB and which, although they are not necessary to meet the need for pharmaceutical services in its area, nevertheless have secured improvements, or better access, to pharmaceutical services in its area;
  - (b) outside the area of the HWB and which, although they do not contribute towards meeting the need for pharmaceutical services in its area, nevertheless have secured improvements, or better access, to pharmaceutical services in its area;
  - (c) in or outside the area of the HWB and, whilst not being services of the types described in sub-paragraph (a) or (b), or paragraph 1, they nevertheless affect the assessment by the HWB of the need for pharmaceutical services in its area.

**Improvements and better access: gaps in provision**

4. A statement of the pharmaceutical services that the HWB has identified (if it has) as services that are not provided in the area of the HWB but which the HWB is satisfied—
  - (a) would, if they were provided (whether or not they were located in the area of the HWB), secure improvements, or better access, to pharmaceutical services, or pharmaceutical services of a specified type, in its area,
  - (b) would, if in specified future circumstances they were provided (whether or not they were located in the area of the HWB), secure future improvements, or better access, to pharmaceutical services, or pharmaceutical services of a specified type, in its area.

**Other NHS services**

5. A statement of any NHS services provided or arranged by a local authority, the NHSCB, a CCG, an NHS trust or an NHS foundation trust to which the HWB has had regard in its assessment, which affect—

- (a) the need for pharmaceutical services, or pharmaceutical services of a specified type, in its area; or
- (b) whether further provision of pharmaceutical services in its area would secure improvements, or better access, to pharmaceutical services, or pharmaceutical services of a specified type, in its area.

**How the assessment was carried out**

**6.** An explanation of how the assessment has been carried out, and in particular—

- (a) how it has determined what are the localities in its area;
- (b) how it has taken into account (where applicable)—
  - (i) the different needs of different localities in its area, and
  - (ii) the different needs of people in its area who share a protected characteristic; and
- (c) a report on the consultation that it has undertaken.

**Map of provision**

**7.** A map that identifies the premises at which pharmaceutical services are provided in the area of the HWB.

Source: [http://www.legislation.gov.uk/uksi/2013/349/pdfs/uksi\\_20130349\\_en.pdf](http://www.legislation.gov.uk/uksi/2013/349/pdfs/uksi_20130349_en.pdf)